Department of Anesthesiology, Vanderbilt University Medical Center, 1161 21st Avenue South, T-4202, MCN, Nashville, TN, 37232, USA.
Department of Anesthesiology and Pain Medicine, University of Alberta, Edmonton, AB, Canada.
Can J Anaesth. 2021 Mar;68(3):409-422. doi: 10.1007/s12630-020-01894-z. Epub 2021 Jan 6.
Present clinical updates, current research findings, and consensus statements relevant to the care of the acute kidney injury (AKI) patient.
Acute kidney injury is one of the most frequent and debilitating complications of surgery and critical illness. Consensus criteria use serum creatinine and urine output measurements to diagnose AKI and allow for objective diagnosis and more accurate comparisons across populations. New serum and urine biomarkers may provide earlier evidence of AKI, but their clinical utility, while increasing, remains limited. Avoidance of nephrotoxins, intravascular fluid management, and maintenance of renal perfusion are the mainstays of preventive management and treatment of AKI. Optimal timing for the initiation of renal replacement therapy is controversial and remains under investigation.
Acute kidney injury continues to affect large numbers of patients receiving surgery or in the intensive care unit, but specific advances in resuscitation techniques, endpoint refinements, epidemiology, biomarkers, and pathology are providing the necessary framework to reduce AKI and associated morbidity.
介绍与急性肾损伤(AKI)患者护理相关的最新临床进展、当前研究结果和共识声明。
急性肾损伤是手术和危重病最常见和最具致残性的并发症之一。共识标准使用血清肌酐和尿量测量来诊断 AKI,并允许进行客观诊断和更准确的人群间比较。新的血清和尿液生物标志物可能更早地提供 AKI 的证据,但它们的临床实用性虽然在增加,但仍然有限。预防管理和治疗 AKI 的主要方法是避免肾毒性药物、血管内液管理和维持肾灌注。开始肾脏替代治疗的最佳时机存在争议,仍在研究中。
急性肾损伤仍然影响大量接受手术或在重症监护病房的患者,但复苏技术、终点细化、流行病学、生物标志物和病理学方面的具体进展为减少 AKI 和相关发病率提供了必要的框架。